Literature DB >> 9595213

Management strategies for a better outcome in unstable coronary artery disease.

R W Campbell1, L Wallentin, F W Verheugt, A G Turpie, A Maseri, W Klein, J G Cleland, C Bode, R Becker, J Anderson, M E Bertrand, C R Conti.   

Abstract

Unstable coronary artery disease is a term encompassing both unstable angina and non-Q-wave (non-ST-segment elevation) myocardial infarction. Patients with these conditions are at risk of early progression to acute myocardial infarction and death. Thus, management of these conditions must aim to reduce long-term mortality and morbidity. Risk stratification is crucial for the identification of patients whose risk of early progression is high; they may require coronary angiography and (if suitable) either percutaneous transluminal coronary angioplasty or coronary artery bypass surgery. No single variable can accurately predict risk, but considerable data are emerging to show that biochemical markers of myocardial injury, such as troponin-T and troponin-I, are valuable in combination with electrocardiographic findings and clinical features. Routine early invasive procedures (coronary angiography with or without revascularization) have not yet been shown to have any significant advantage over conservative regimens for the majority of patients. Antiplatelet, anticoagulant, and anti-ischemic agents remain the mainstay of treatment in the acute phase. New agents, such as glycoprotein IIb/IIIa receptor inhibitors and low-molecular-weight heparins, as well as antithrombins and Factor Xa inhibitors add to the treatments currently available. Thrombolytic agents are contraindicated in the absence of ST-segment elevation. After clinical stabilization, ongoing assessment should include exercise testing for all patients who are able; other imaging techniques should be used for patients unable to exercise. A profile indicating a high risk of future events is an indication for elective angiography and consideration for revascularization.

Entities:  

Mesh:

Year:  1998        PMID: 9595213      PMCID: PMC6655264          DOI: 10.1002/clc.4960210504

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  47 in total

1.  Rapid thrombus dissolution by continuous infusion of urokinase through an intracoronary perfusion wire prior to and following PTCA: results in native coronaries and patent saphenous vein grafts.

Authors:  A T Chapekis; B S George; R J Candela
Journal:  Cathet Cardiovasc Diagn       Date:  1991-06

Review 2.  Insights into the pathogenesis of acute ischemic syndromes.

Authors:  V Fuster; L Badimon; M Cohen; J A Ambrose; J J Badimon; J Chesebro
Journal:  Circulation       Date:  1988-06       Impact factor: 29.690

3.  Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group.

Authors:  S H Hohnloser; T Meinertz; T Klingenheben; B Sydow; H Just
Journal:  Am J Cardiol       Date:  1991-06-15       Impact factor: 2.778

4.  Aspirin, heparin, or both to treat acute unstable angina.

Authors:  P Théroux; H Ouimet; J McCans; J G Latour; P Joly; G Lévy; E Pelletier; M Juneau; J Stasiak; P deGuise
Journal:  N Engl J Med       Date:  1988-10-27       Impact factor: 91.245

5.  Reactivation of unstable angina after the discontinuation of heparin.

Authors:  P Théroux; D Waters; J Lam; M Juneau; J McCans
Journal:  N Engl J Med       Date:  1992-07-16       Impact factor: 91.245

6.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

Authors:  S Yusuf; C J Pepine; C Garces; H Pouleur; D Salem; J Kostis; C Benedict; M Rousseau; M Bourassa; B Pitt
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

7.  Predictors of risk in patients with unstable angina admitted to a district general hospital.

Authors:  J J Murphy; P A Connell; J R Hampton
Journal:  Br Heart J       Date:  1992-05

8.  Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. The RISC Group.

Authors: 
Journal:  Lancet       Date:  1990-10-06       Impact factor: 79.321

9.  Early treatment of unstable angina in the coronary care unit: a randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Report of The Holland Interuniversity Nifedipine/Metoprolol Trial (HINT) Research Group.

Authors: 
Journal:  Br Heart J       Date:  1986-11

10.  Early exercise testing after coronary care for suspected unstable coronary artery disease--safety and diagnostic value.

Authors:  E Swahn; M Areskog; L Wallentin
Journal:  Eur Heart J       Date:  1986-07       Impact factor: 29.983

View more
  2 in total

Review 1.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

2.  Systemic Inflammatory Response Syndrome Predicts Mortality in Acute Coronary Syndrome without Congestive Heart Failure.

Authors:  Matías José Fosco; Victoria Ceretti; Daniel Agranatti
Journal:  West J Emerg Med       Date:  2010-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.